Check out the BioBytes (an In Vivo blog) quarterly AI-related biopharma deal summary for a snapshot of the fundraising, partnership and M&A landscape. In Q2, AI-related biopharma deals were dominated by Xaira Therapeutics's $1bn venture inancing, but the quarter was also notable for sizeable public offerings by Alumis and Recursion in the US and XtalPi Inc. in Hong Kong, as well as a $142m seed round for EvolutionaryScale. Citeline Commercial
David Wild’s Post
More Relevant Posts
-
#BioBytes presents an overview of #AI-related #biopharma deals in Q1 2024. This is the first in a recurring series of quarterly deal updates. Free to view. https://lnkd.in/d2h37NxG
BioBytes: AI-Related Deals In Q1 2024
invivo.citeline.com
To view or add a comment, sign in
-
In the first of an ongoing series looking at quarterly dealmaking, BioBytes presents an overview of select AI-focused M&As, partnerships and financings in the biopharma industry in Q1 2024. Access an overview of the types of AI technologies pharma companies and investors are placing a premium on at the moment and who the big AI players are. Review the Q1 Deals: https://ow.ly/sB8E50RypI4. #BioPharmaAI #Biotech #VentureCapital #AIinHealthcare #TechInvesting #ArtificialIntelligence
BioBytes: AI-Related Deals In Q1 2024
invivo.citeline.com
To view or add a comment, sign in
-
In the first of an ongoing series looking at quarterly dealmaking, BioBytes presents an overview of select AI-focused M&As, partnerships and financings in the biopharma industry in Q1 2024. Access an overview of the types of AI technologies pharma companies and investors are placing a premium on at the moment and who the big AI players are. Review the Q1 Deals: https://ow.ly/xuvj50RypQM. #BioPharmaAI #Biotech #VentureCapital #AIinHealthcare #TechInvesting #ArtificialIntelligence
BioBytes: AI-Related Deals In Q1 2024
invivo.citeline.com
To view or add a comment, sign in
-
In the first of an ongoing series looking at quarterly dealmaking, BioBytes presents an overview of select AI-focused M&As, partnerships and financings in the biopharma industry in Q1 2024. Access an overview of the types of AI technologies pharma companies and investors are placing a premium on at the moment and who the big AI players are. Review the Q1 Deals: https://ow.ly/msmy50RypwN. #BioPharmaAI #Biotech #VentureCapital #AIinHealthcare #TechInvesting #ArtificialIntelligence
BioBytes: AI-Related Deals In Q1 2024
invivo.citeline.com
To view or add a comment, sign in
-
What's the #dealmaking environment like for AI-focused #biopharma and #biotech companies? Have a look at the table I've put together below highlighting 28 Q1 2024 deals and financings, including dollar values, disease indications and deal details, including VC firms providing funding. Free to read. Citeline Commercial
BioBytes: AI-Related Deals In Q1 2024
invivo.citeline.com
To view or add a comment, sign in
-
In phase 2 in particular it is difficult to assess the trade-off between being as quick as possible versus being as careful as possible to set up the phase 3 correctly - for instance by by better characterizing the dose response. We will look at estimating the expected net present value of the development program across a range of phase 2 trial options as one way to make that assessment.
Berry Consultants will be hosting a free public webinar on the optimization of a clinical trial design by estimating its impact on the expected net present value (or ROI) of a drug development program using the software, QUOTES (Quantification and Optimization of Trial Expectations Simulator). This Zoom webinar will be next Friday, Feb 23 at 11:00AM EST at the following link: https://lnkd.in/gUYr-dn9 Plan on joining us then!
To view or add a comment, sign in
-
-
ICYMI: We updated our Clinical Trials Finder! What's new? Upgrades allow you to: -Create a profile to access saved filters and subscribe to receive email notifications on new trial listings -Search hundreds of trials based on condition, drug, and trial identifier, and bookmark what you find to view later -Share the trial or a list of trials with others via email, print PDF, or social media Check it out here: https://lnkd.in/gDpwYw2u #PatientEducation
To view or add a comment, sign in
-
-
📢 Elevate your knowledge with our weekly newsletter! Have you joined the conversation? 🌐 📖 Read articles from industry leading experts and their recent advancements in the drug world. You'll also discover the latest in drug discoveries every Wednesday morning! 📆 Set a date with your LinkedIn page – our newsletter lands conveniently in your feed. Ready to stay in the know? Sign up now 👉 https://bit.ly/3u4OLyt #StayInformed #IndustryInsights #NewsletterAlert 📬
To view or add a comment, sign in
-
-
📢 Elevate your knowledge with our weekly newsletter! Have you joined the conversation? 🌐 📖 Read articles from industry leading experts and their recent advancements in the drug world. You'll also discover the latest in drug discoveries every Wednesday morning! 📆 Set a date with your LinkedIn page – our newsletter lands conveniently in your feed. Ready to stay in the know? Sign up now 👉 https://bit.ly/3u4OLyt #StayInformed #IndustryInsights #NewsletterAlert 📬
To view or add a comment, sign in
-
-
Phase I #clinicaltrials are essential for early drug development and Signant SmartSignals® Unified Platform addresses their unique needs. Discover how our quick-to-deploy #EDC and #eConsent modules facilitate fast-paced Phase I trials: https://bit.ly/43mMuf4
See how our integrated technology platform is reshaping Phase I research
resources.signanthealth.com
To view or add a comment, sign in